检索结果-南通市图书馆

chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus(Version 2024)

在线全文

学校读者我要写书评

暂无评论

infectious Microbes & diseases 2024年第3期6卷 108-116页

作者： Jinfeng Liu Qinglei Zeng Fanpu Ji Hong Ren Wenhong Zhang Lanjuan Li Yingren Zhao infectious diseases Physicians Branch of chinese medical Doctor association chinese society of infectious diseases of chinese medical association The First Affiliated Hospital of Xi’an Jiaotong University Xi’anChina Shaanxi Clinical medical Research Center of infectious diseases Xi’anChina The First Affiliated Hospital of Zhengzhou University ZhengzhouChina The Second Affiliated Hospital of Xi’an Jiaotong University Xi’anChina The Second Affiliated Hospital of Chongqing medical University ChongqingChina Huashan Hospital Fudan UniversityShanghaiChina State Key Laboratory for the Diagnosis and Treatment of infectious diseases The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina 不详

The chinese Clinical Practice Guidelines for the prevention and treatment ofmother-to-child transmission of hepatitis B virus,developed by the chinese society of infectious diseases of the chinese medical association in 2019,serves as a valuable reference for standardizing the process of preventing mother-to-child transmission in *** new evidence emerges,it is crucial that timely and regular updates are made to the clinical practice guidelines so as to optimize guidance for clinical practice and *** this end,the infectious Disease Physician Branch of chinese medical Doctor association and the chinese society of infectious diseases of chinese medical association,in collaboration with multidisciplinary experts,have updated the guidelines based on the latest domestic and international research advancements and clinical practice,in order to provide guidance and reference for clinicians andmaternal and child healthcare workers.

关键词： guidelines hepatitis B virus mother-to-child transmission prevention treatment update

chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第3期21卷 251-314页

作者： Chang-Sheng MA Shu-Lin WU Shao-Wen LIU Ya-Ling HAN chinese society of Cardiology chinese medical association Heart Rhythm Committee of chinese society of Biomedical Engineering Beijing Anzhen Hospital Capital Medical University Guandong Provincial People’s Hospital Shanghai First People’s Hospital General Hospital of Northern Theater Command 不详

Atrial fibrillation(AF)is the most common sustained cardiac arrhythmia,significantly impacting patients’quality of life and increasing the risk of death,stroke,heart failure,and *** the past two decades,there have been significant breakthroughs in AF risk prediction and screening,stroke prevention,rhythm control,catheter ablation,and integrated *** this period,the scale,quality,and experience of AF management in China have greatly improved,providing a solid foundation for the development of guidelines for the diagnosis and management of *** further promote standardized AF management,and apply new technologies and concepts to clinical practice in a timely and comprehensive manner,the chinese society of Cardiology of the chinese medical association and the Heart Rhythm Committee of the chinese society of Biomedical Engineering have jointly developed the chinese Guidelines for the Diagnosis and Management of Atrial *** guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2-VASc-60 stroke risk score based on the characteristics of AF in the Asian *** guidelines have also reevaluated the clinical application of AF screening,emphasized the significance of early rhythm control,and highlighted the central role of catheter ablation in rhythm control.

关键词： prevention sustained diagnosis

Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children

在线全文

学校读者我要写书评

暂无评论

infectious diseases & Immunity 2024年第3期4卷 106-120页

作者： chinese society of infectious diseases chinese medical association chinese society of hepatology chinese medical association Group of infectious diseases chinese Pediatric society chinese medical association National Clinical Research Center for infectious diseases(Beijing) Fu-Sheng Wang Shishu Zhu Min Zhang Jianshe Wang Shuangjie Li Junliang Fu Yuanyuan Li Yuming Guo Jing Li Hongmei Xu Wenxian Ouyang Yuemin Nan Sainan Shu Shuangsuo Dang Xiaoyuan Xu Taisheng Li Jinlin Hou 不详 The Fifth medical Center of PLA General Hospital Beijing 100039China Fudan University Children’s Hospital Hunan Children’s Hospital Children’s Hospital of Chongqing medical University Third Hospital Hebei Medical University Tongji Hospital Tongji Medical CollegeHuazhong University of Science and Technology The Second Affiliated Hospital of Xi’an Jiaotong University Peking University First Hospital Peking Union medical College Hospital Chinese Academy of Medical Sciences&Peking Union Medical College Nanfang Hospital Southern Medical University

The aim of this consensus is to standardize the prevention, diagnosis, and treatment of chronic hepatitis B in children and to achieve the goal of “eliminating viral hepatitis as a major public health threat by 2030” issued by the World Health Organization. Formulated by organized experts of the chinese society of infectious diseases and chinese society of hepatology, chinese medical association;Group of infectious diseases, chinese Pediatric society, chinese medical association;and the National Clinical Research Center for infectious diseases (Beijing), the consensus provides the latest evidence and recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B in children.

关键词： Chronic hepatitis B Children Treatment Prevention Consensus

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological society(CPS) Expert Committee on Lymphoma of chinese society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese society of Clinical Oncology(CSCO) society of Integrative Cardio-Oncology of China Anti-Cancer association(CACA) chinese society of Hematology of chinese medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第17期137卷 2024 Aug 6页

作者： Li Jingnan Yao Hongwei Lu Yun Zhang Shutian Zhang Zhongtao society of Digestive Endoscopy of the chinese medical association Colorectal Surgery Group of the chinese medical association chinese association of Gastroenterologist & Hepatologist National Clinical Research Center for Digestive diseases chinese medical Journal Clinical Practie Guideline Collaborative Department of Gastroenterology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China Department of General Surgery Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Diseases Beijing China Department of General Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong China Department of Gastroenterology Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Disease Beijing China

Background: The incidence and mortality of colorectal cancer (CRC) in China are increasing in recent years. The clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent, screen, and diagnose CRC at an early stage. With the development of endoscopic and surgical techniques, the choice of treatment for early CRC is also worth further discussion, and accordingly, a standard follow-up program after treatment needs to be ***: This clinical practice guideline (CPG) was developed following the recommended process of the World Health Organization, adopting Grading of Recommendations Assessment, Development and Evaluation (GRADE) in assessing evidence quality, and using the Evidence to Decision framework to formulate clinical recommendations, thereby minimizing bias and increasing transparency of the CPG development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline’s completeness and ***: This CPG comprises 46 recommendations concerning prevention, screening, diagnosis, treatment, and surveillance of CRC. In these recommendations, we have indicated protective and risk factors for CRC and made recommendations for chemoprevention. We proposed a suitable screening program for CRC based on the chinese context. We also provided normative statements for the diagnosis, treatment, and surveillance of CRC based on existing clinical evidence and ***: The 46 recommendations in this CPG are formed with consideration for stakeholders’ values and preferences, feasibility, and acceptability. Recommendations are generalizable to resource-limited settings with similar CRC epidemiology pattern as China.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up Guideline

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji society of Digestive Endoscopy of the chinese medical association Colorectal Surgery Group of the chinese medical association chinese association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive diseases chinese medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in China are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

2023 chinese national clinical practice guideline on diagnosis and management of ulcerative colitis

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 1642-1646页

作者： Inflammatory Bowel Disease Group, chinese society of Gastroenterology, chinese medical association Inflammatory Bowel Disease Quality Control Center of China Inflammatory Bowel Disease Group Chinese Society of Gastroenterology Chinese Medical Association Inflammatory Bowel Disease Quality Control Center of China

The role of chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease (IBD) is self-evident. As clinical and basic research in China becomes standardized under a better understanding of IBD, more data on chinese patients have become available to develop a consensus and guideline. This guideline, collaboratively developed by the IBD Group, chinese society of Gastroenterology, incorporates the latest international consensus statements, domestic research findings, and practical considerations, as an update based on the 2018 chinese consensus on IBD management. The IBD guideline consists of two parts: ulcerative colitis (UC) and Crohn's disease, and this manuscript presented the UC part. The evidence used in this guideline was collected and analyzed by the standard of guideline, and the contents were organized as problem statements, for clarity. The formulation of this guideline aimed to reflect the latest progress in IBD, providing comprehensive and valuable guidance for the clinical management of IBD.

关键词：

2023 Guideline for the management of hypertension in the elderly population in China

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第6期21卷 589-630页

作者： Hypertension Branch of chinese Geriatrics society,Beijing Hypertension association,National Clinical Research Center of the Geriatric diseases Qi HUA Li FAN Zeng-Wu WANG Jing LI 不详 Xuanwu Hospital Capital Medical UniversityBeijingChina chinese PLA General Hospital BeijingChina Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Preamble Hypertension is one of the most common chronic diseases and the primary risk factor for stroke,myocardial infarction and even cardiovascular *** than half of the elderly population has high blood *** people are a unique group,and strategies for the prevention,diagnosis,evaluation,and treatment of hypertension in elderly individuals differ significantly from those in the general population.

关键词： hypertension prevention diagnosis

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

在线全文

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第9期137卷 1016-1018页

作者： The society of Cancer Precision Medicine of chinese Anti-Cancer association The Lung Cancer Expert Group of chinese medical association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory Medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the society of Cancer Precision Medicine of chinese Anti-Cancer association and the Lung Cancer Expert Group of chinese medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung